Selected nontransplant trials for newly-diagnosed patients
| Reference . | Phase . | Name of trial . | Arm . | N . | PFS* . | HR . | ORR . | ≥VGPR . | ≥CR . |
|---|---|---|---|---|---|---|---|---|---|
| Benboubker et al64 | 3 | FIRST | MPT | 547 | 21.2 | 62% | 28% | 9% | |
| Rd 18 | 541 | 20.7 | 73% | 43% | 14% | ||||
| Rd cont. | 535 | 25.5 | 0.72† | 75% | 44% | 15% | |||
| Durie et al6 | 3 | SWOG S0777 | VRd | 264 | 43 | 0.712 | 81.5% | 43.5% | 15.7% |
| Rd | 261 | 30 | 71.5% | 31.8% | 8.4% | ||||
| O’Donnell et al8 | 2 | RVD lite | RVd | 50 | 90%‡ | 60% | 25% | ||
| Niesvizky et al13 | 3B | UPFRONT | Vd | 168 | 14.7 | 73% | 37% | 3% | |
| VTd | 167 | 15.4 | 80% | 51% | 4% | ||||
| VMP | 167 | 17.3 | 70% | 41% | 4% | ||||
| Mateos et al14 | 3 | GEM2005 | VMP | 130 | 34 | 80% | 20% | ||
| VTP | 130 | 25 | 81% | 28% | |||||
| #NCT02252172 | 3 | MAIA | Rd-dara | Ongoing | |||||
| Rd | |||||||||
| #NCT01850524 | 3 | TOURMALINE-MM2 | IRd | Closed to accrual | |||||
| Rd | |||||||||
| Reference . | Phase . | Name of trial . | Arm . | N . | PFS* . | HR . | ORR . | ≥VGPR . | ≥CR . |
|---|---|---|---|---|---|---|---|---|---|
| Benboubker et al64 | 3 | FIRST | MPT | 547 | 21.2 | 62% | 28% | 9% | |
| Rd 18 | 541 | 20.7 | 73% | 43% | 14% | ||||
| Rd cont. | 535 | 25.5 | 0.72† | 75% | 44% | 15% | |||
| Durie et al6 | 3 | SWOG S0777 | VRd | 264 | 43 | 0.712 | 81.5% | 43.5% | 15.7% |
| Rd | 261 | 30 | 71.5% | 31.8% | 8.4% | ||||
| O’Donnell et al8 | 2 | RVD lite | RVd | 50 | 90%‡ | 60% | 25% | ||
| Niesvizky et al13 | 3B | UPFRONT | Vd | 168 | 14.7 | 73% | 37% | 3% | |
| VTd | 167 | 15.4 | 80% | 51% | 4% | ||||
| VMP | 167 | 17.3 | 70% | 41% | 4% | ||||
| Mateos et al14 | 3 | GEM2005 | VMP | 130 | 34 | 80% | 20% | ||
| VTP | 130 | 25 | 81% | 28% | |||||
| #NCT02252172 | 3 | MAIA | Rd-dara | Ongoing | |||||
| Rd | |||||||||
| #NCT01850524 | 3 | TOURMALINE-MM2 | IRd | Closed to accrual | |||||
| Rd | |||||||||
d, dexamethasone; dara, daratumumab; FIRST, Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide; GEM, Grupo Español de Mieloma; I, ixazomib; M, melphalan; P, prednisone; R, lenalidomide; T, thalidomide; V, bortezomib; VTP, bortezomib, thalidomide, and prednisone.
Median PFS in months.
HR of Rd continuous vs MPT.
Response rates are after four cycles of treatment in 40 patients.